Articles tagged "Co-stimulation"

2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
I. Tawhari¹, P. Hallak¹, S. Hartzell², V. Mas³, P. Cravedi², J. Leventhal¹, J. Ansari¹, L. Gallon¹
¹Northwestern University, Chicago, IL, ²Mount Sinai, New York, NY, ³University of Maryland, Baltimore, MD
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…
2022 American Transplant Congress
Renal Function at Five Years from a Randomized Multicenter Trial of Belatacept-Based CNI Free and Early Steroid Withdrawal Immunosuppression
E. Yanqui¹, H. Hames¹, A. R. Shields¹, T. Shi¹, A. L. Christianson¹, J. Kremer², A. Govil¹, R. R. Alloway¹, E. S. Woodle¹
¹University of Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: BENEFIT and BENEFIT EXT trials have demonstrated that belatacept-based immunosuppression was associated with improved long term renal allograft function compared to cyclosporine-based immunosuppression. Similar…
2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
A. Rizvi¹, M. Kueht², S. Hussain³, J. Fair², R. Ramirez⁴, A. Gamilla-Crudo⁵, M. Mujtaba⁵
¹Internal Medicine, Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX, ²Surgery, University of Texas Medical Branch, Galveston, TX, ³University of Texas Medical Branch, Houston, TX, ⁴Surgery, University of Texas Medical Branch at Galveston, Galveston, TX, ⁵University of Texas Medical Branch, Galveston, TX
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
2022 American Transplant Congress
Tolerant B Cells Suppress Memory B Cells in a Donor Specific Manner in CoB Mediated Transplantation Tolerance
S. Durgam¹, D. Yin¹, M. Alegre², A. Chong¹
¹Surgery, section of transplant immunology, University of Chicago, Chicago, IL, ²Medicine, section of rheumatology, University of Chicago, Chicago, IL
*Purpose: We previously reported that B cells in recipients made tolerant to fully mismatched heart allografts by anti-CD154+donor spleen cells (CoB) become dysfunctional in their…
2022 American Transplant Congress
Donor-Specificb Cell Dysfunction and Suppressive Ability Are Differentially Induced in Cob-Mediated Transplantation Tolerance
S. Durgam¹, D. Yin¹, M. Alegre², A. Chong¹
¹Surgery, section of transplant immunology, University of Chicago, Chicago, IL, ²Medicine, section of rheumatology, University of Chicago, Chicago, IL
*Purpose: B cells in mice tolerized to fully mismatched heart allografts with anti-CD154+donor spleen cells (CoB) are intrinsically dysfunctional and unable to differentiate into germinal…
2022 American Transplant Congress
Belatacept Augments Mixed Chimerism in a Novel Nonhuman Primate Kidney Transplant Tolerance Induction Protocol
S. C. Kim, C. J. Little, J. H. Fechner, P. J. Chlebeck, J. Post, A. D'Alessandro, D. B. Kaufman
University of Wisconsin, Madison, WI
*Purpose: A novel protocol of antilymphocyte globulin (ATG), tomotherapy-based total lymphoid irradiation (TomoTLI), and adoptive cellular transfer was developed in a preclinical model of MHC-mismatched…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Obesity Impacts Acute Rejection but Not Allograft Function Improvement in the Setting of Belatacept Conversion
D. Pierce, J. Benken, P. West-Thielke, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: There is limited data regarding belatacept conversion in obese patients as an alternative to calcineurin inhibitor (CNI) immunosuppression. Pharmacokinetic (PK) data suggests increasing clearance…
2021 American Transplant Congress
P40 Homodimers Induce Il-15 to Promote Endogenous Donor-reactive Memory Cd8 T Cell Activation within High-risk Cardiac Allografts
H. Tsuda, A. Valujskikh, R. Fairchild
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Longer cold ischemic storage (CIS) time prior to transplant results in increased proliferation of endogenous donor-reactive memory CD8 T cells within complete MHC-mismatched cardiac…
2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen
R. E. Scalzo, M. T. Harris, J. D. Morris, J. S. Byrns
Pharmacy, Duke University Medical Center, Durham, NC
*Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…